How Psychedelics Returned to Science
In the middle of the twentieth century, two powerful substances entered Western awareness. One was LSD, first discovered by Swiss chemist Albert Hofmann while working in a lab. The other was psilocybin, the active compound in certain mushrooms long used in Indigenous ceremonies in Mexico. At first, psychiatrists saw both as promising tools for understanding the mind and treating suffering.
That early promise did not last. By the 1960s, these drugs had escaped the clinic and become tied to rebellion, youth culture, and public alarm. Governments responded with strict bans, and research nearly disappeared for decades. What had once seemed like a breakthrough in psychiatry came to be treated as a social threat.
Years later, interest returned quietly and carefully. A key turning point came in 2006, when a Johns Hopkins study showed that psilocybin could reliably produce deeply meaningful experiences under controlled conditions. Around the same time, legal rulings protected limited religious use of psychedelic plants, and respected scientists began reopening questions that had long been shut down. The field regained credibility because it moved slowly, emphasized safety, and focused on measurable outcomes.
At the center of this revival was Roland Griffiths, an unlikely pioneer. He had built his career as a rigorous researcher studying addiction and behavior, not spirituality. Yet he became interested in whether science could study profound states of consciousness without losing its standards. Working with colleagues such as Bob Jesse and Bill Richards, he helped build a bridge between modern clinical research and experiences that many people describe in spiritual terms.
The most striking finding from this work was that a single guided psychedelic session could leave lasting effects. Volunteers often reported a temporary loss of ego, a sense that the usual boundaries of the self had fallen away. Many felt connected to nature, to other people, or to something larger than themselves. Even when they struggled to describe what happened, they often came away convinced that the experience had shown them something important.
The setting mattered as much as the drug. Sessions took place in warm, quiet rooms rather than cold hospital spaces, and trained guides helped people prepare for fear and uncertainty. Participants were encouraged not to flee difficult images or feelings, but to face them with curiosity. This simple shift often turned panic into insight, and confusion into relief.
For people facing serious illness, the results could be especially powerful. In studies with cancer patients, many reported that their fear of death became far less overwhelming. The change did not come from being talked out of their fear. It came from directly experiencing a state in which the self seemed larger, less fragile, and less limited to the body alone.
Full summary available in the Readsome app
